De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast

Conditions

• HER2-positive Breast Cancer

Interventions

• DRUG: THP×4 Q3W (n=296) (Investigator-selected taxane* + Trastuzumab IV 6 mg/kg, loading dose 8 mg/kg + Pertuzumab IV 420 mg, loading dose 840mg)
• DRUG: THP×6 Q3W (n=296) (Investigator-selected taxane* + Trastuzumab IV 6 mg/kg, loading dose 8 mg/kg + Pertuzumab IV 420 mg, loading dose 840mg)

Sponsor

Guangdong Provincial People's Hospital